Test of Amgen D-mab Drug Confirms Earlier Results

An experimental osteoporosis drug that is considered to be crucial to the future of biotechnology giant Amgen strengthened bones more than today's most widely-used treatment, research showed.

Researchers report at a scientific conference in Spain today that the twice-a-year injectable drug known as D-mab increased bone mineral density - a key measure of its effectiveness - 40 percent more than Fosamax.

Doctors say the 1100 women on Amgen's D-mab or on Fosamax experienced similar side effects including joint and back pain, indigestion and constipation.

In a press release, the company did not mention any infections, which some analysts have recently expressed concern over.

Results of a much bigger, 8,000-patient D-mab study that will likely determine the drug's fate are expected later this year.

Fosamax is made by Merck , but went generic a few months ago.

The detailed data out today confirm headline results that Amgen released back in January.

Contact Health Care


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More